Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 71
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Pediatr Infect Dis J ; 10(9): 658-62, 1991 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-1923678

RESUMEN

There is a paucity of published information available on extrapulmonary cryptococcosis (EC) in children infected with human immunodeficiency virus, the etiologic agent of the acquired immunodeficiency syndrome. We surveyed investigators in pediatric acquired immunodeficiency syndrome around the country regarding their experience with EC. Investigators from 33 (87%) of 38 institutions responded and information on 13 patients from 11 institutions was analyzed. EC was the acquired immunodeficiency syndrome indicator disease in 9 (69%) of 13 patients. Median age was 8 years with a range of 2 to 17 years. Human immunodeficiency virus risk factors were transfusion (5 patients), hemophilia (4 patients) and perinatal exposure (4 patients). Meningitis, seen in 62% of patients, was the most common clinical manifestation. Although 2 patients with fulminant disease died before therapy was started, 10 (91%) of 11 had a clinical response to amphotericin B with or without flucytosine. Our study indicates a spectrum of EC in pediatric human immunodeficiency virus infection ranging from fulminant, fatal fungemia to chronic meningitis and fever of unknown origin. Cryptococcosis was generally not the cause of death in patients who initially responded to amphotericin B therapy. Optimal antifungal therapy, including the role of fluconazole, warrants further study.


Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Criptococosis/complicaciones , Infecciones Oportunistas/complicaciones , Adolescente , Niño , Preescolar , Criptococosis/diagnóstico , Femenino , Fungemia/complicaciones , Humanos , Masculino , Meningitis Criptocócica/complicaciones
2.
Pediatr Infect Dis J ; 14(4): 267-9, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7603806

RESUMEN

There is little information on prophylactic antibiotic practice in pediatric cardiovascular surgery. A consensus prophylactic antibiotic practice, if identified, might serve as a standard to which alternative prophylactic antibiotic practice could be compared. We surveyed North American academic centers with pediatric cardiovascular surgery programs regarding their standard antimicrobial prophylaxis regimens, duration of prophylaxis and modification of prophylaxis for lesion, patient age or medical device considerations. Forty-three (81%) of 53 centers responded; not all responses were complete. Monotherapy was used by 39 (91%) of 43; 38 (97%) of 39 used a 1st or 2nd generation cephalosporin (cefazolin 24, cefamandole 8, cefuroxime 4, cephapirin 1, unspecified 1) and 1 of 39 used vancomycin. Only 4 (9%) of 43 used 2 antibiotics. Prophylactic antibiotics were started pre- or intraoperatively by 41 of 43 centers and discontinued within 2 days by 25 of 37. Prophylactic antibiotics were often continued while thoracostomy tubes (29 of 43), mediastinal tubes (31 of 43) or transthoracic vascular catheters (22 of 43) were in place, but usually not for endotracheal tubes (6 of 43), arterial (9 of 43) or percutaneous central venous (13 of 43) catheters or temporary pacing wires (6 of 43). Our survey indicates that the consensus prophylactic antibiotic regimen for pediatric cardiovascular surgery is monotherapy with a first or second generation cephalosporin, used for < or = 2 days or until transthoracic medical devices are removed.


Asunto(s)
Antibacterianos/uso terapéutico , Procedimientos Quirúrgicos Cardíacos , Premedicación , Cefalosporinas/uso terapéutico , Niño , Humanos , Pediatría , Infección de la Herida Quirúrgica/prevención & control , Encuestas y Cuestionarios
3.
Pediatr Infect Dis J ; 14(4): 278-81, 1995 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7603808

RESUMEN

There is little information available on invasive group B Streptococcus (GBS) infection in pediatric patients older than 3 months of age. Review of infection control records at LeBonheur Children's Medical Center from January 1, 1986, to June 30, 1993, identified 143 patients with a positive GBS culture from normally sterile body fluid. Medical records of 18 (13%) patients > 3 months old with their first GBS infection were reviewed. Age range was 15 weeks to 18 years (median age, 13 months). Ten were black and 11 were girls. Five infants had a history of premature birth and 2 infants were infected with human immunodeficiency virus. The serotype distribution of 12 available GBS isolates was 4 type III, 2 each type V and Ia and 1 each type Ia/c, Ib/c, II and II/c. Bacteremia without a focus (9 patients) was the most common clinical manifestation. All 4 type III isolates were associated with bacteremia. One infant with human immunodeficiency virus infection had sepsis and bullous desquamation; a toxin-producing type V strain was isolated from her blood. Two adolescents with ventriculoperitoneal shunts had meningitis, including one whose cerebrospinal fluid also grew a type V strain. Other clinical manifestations were septic arthritis, endocarditis (Ia, II/c), central venous catheter (Ia/c) and ventriculostomy infections.


Asunto(s)
Bacteriemia/epidemiología , Infecciones Estreptocócicas/epidemiología , Streptococcus agalactiae/aislamiento & purificación , Adolescente , Distribución por Edad , Edad de Inicio , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Bacteriemia/fisiopatología , Niño , Preescolar , Femenino , Humanos , Incidencia , Lactante , Masculino , Estudios Retrospectivos , Infecciones Estreptocócicas/tratamiento farmacológico , Infecciones Estreptocócicas/fisiopatología
4.
Infect Control Hosp Epidemiol ; 21(1): 53-6, 2000 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10656359

RESUMEN

Bioterrorism is an emerging public health and infection control threat. Potential biological agents include smallpox, anthrax, plague, tularemia, botulinum toxin, brucellosis, Q fever, viral encephalitis, hemorrhagic fever, and staphylococcal enterotoxin B. An understanding of the epidemiology, clinical manifestations, and management of the more likely candidate agents is critical to limiting morbidity and mortality from a biological event. Effective response requires an increased index of suspicion for unusual diseases or syndromes, with prompt reporting to health authorities to facilitate recognition of an outbreak and subsequent intervention. Hospital epidemiology programs will play a crucial role in this effort.


Asunto(s)
Guerra Biológica , Planificación en Desastres , Carbunco/epidemiología , Carbunco/fisiopatología , Carbunco/prevención & control , Botulismo/microbiología , Botulismo/fisiopatología , Humanos , Peste/tratamiento farmacológico , Peste/epidemiología , Peste/fisiopatología , Viruela/prevención & control , Viruela/transmisión , Tularemia/diagnóstico , Tularemia/tratamiento farmacológico , Tularemia/fisiopatología
5.
Infect Control Hosp Epidemiol ; 15(11): 710-2, 1994 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-7852727

RESUMEN

OBJECTIVE: To determine the incidence and type of antibiotic use variances at our institution. DESIGN: Inpatient bacterial culture and susceptibility results were reviewed for 1 week per month. Medication administration records were evaluated to determine whether antibiotic selection was appropriate, given the susceptibility of the organism. Process indicators included use of the least costly antibiotic, as well as appropriate dose, interval, and route of administration. The complete medical record was reviewed for all patients if management did not appear to meet criteria. SETTING: A 225-bed, tertiary-care children's teaching hospital. RESULTS: Thirty-five (8.2%) of 428 patients reviewed over 12 months had a total of 49 variances: failure to treat (3), treatment of contaminant/colonizer (2), use of more costly agent (10), failure to revise therapy (8), inappropriate route (2), inappropriate empiric antibiotic (4), incorrect dose (3), unnecessary multiple antibiotics (6), inappropriate drug (8), and prolonged prophylaxis (3). CONCLUSIONS: Thirty-five patients with 10 types of variances were identified during the study. Follow-up monitoring will assess the impact of educational efforts on the incidence of variances. Specific problem antibiotics have been identified for further audits.


Asunto(s)
Antibacterianos/uso terapéutico , Revisión de la Utilización de Medicamentos/estadística & datos numéricos , Hospitales Pediátricos/normas , Antibacterianos/economía , Niño , Preescolar , Vías de Administración de Medicamentos , Esquema de Medicación , Hospitales con 100 a 299 Camas , Hospitales de Enseñanza , Humanos , Lactante , Registros Médicos , Pruebas de Sensibilidad Microbiana , Tennessee
6.
Infect Dis Clin North Am ; 11(4): 867-74, 1997 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-9421704

RESUMEN

The prevalence of drug-resistant Streptococcus pneumoniae (DRSP) has increased worldwide. Although unfavorable outcomes in meningitis due to DRSP have been well-described, the clinical impact of DRSP on other manifestations of pneumococcal infection warrants further study. Empiric combination vancomycin and extended-spectrum cephalosporin (cefotaxime or ceftriaxone) therapy is indicated for the following clinical indications: purulent meningitis, life-threatening pneumonia, and suspected sepsis in patients predisposed to invasive pneumococcal disease, for example, sickle cell disease, HIV infection, and nephrotic syndrome. In addition to clinical management issues, other implications of the emergence of DRSP include identification of resistant strains, local and national surveillance, and prevention. Preventive measures include judicious antibiotic use, appropriate use of the currently available 23-valent pneumococcal vaccine, and development and implementation of a protein-conjugate vaccine.


Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Microbiana , Infecciones Neumocócicas/tratamiento farmacológico , Manejo de la Enfermedad , Humanos , Meningitis Neumocócica/diagnóstico , Meningitis Neumocócica/tratamiento farmacológico , Otitis Media/diagnóstico , Otitis Media/tratamiento farmacológico , Infecciones Neumocócicas/epidemiología , Infecciones Neumocócicas/prevención & control , Neumonía Neumocócica/diagnóstico , Neumonía Neumocócica/tratamiento farmacológico
7.
Diagn Microbiol Infect Dis ; 4(3 Suppl): 61S-69S, 1986 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-3009084

RESUMEN

The accurate diagnosis of infectious diseases is important for the optimal management of infected patients as well as for the prevention of disease transmission to susceptible individuals. Because viral gastroenteritis constitutes an important cause of morbidity in children living in developed countries and of mortality in children living in developing countries, there has been a great deal of interest in the development of effective methods for the diagnosis and study of this disease. While there are a number of assay systems that are capable of accurate detection of the agents of viral gastroenteritis in the intestinal contents of infected individuals, solid phase enzyme immunoassays have been used widely for this purpose. The widespread utilization of enzyme immunoassays is based on the advantages inherent in the use of enzymatic markers. These advantages include the stability of enzyme-immunoglobulin conjugates, the high degree of sensitivity inherent in the magnifying nature of enzyme-substrate interactions, and the low cost of assays performed in simple reaction formats. Enzyme immunoassays have thus been developed and widely used for the detection and epidemiologic study of rotaviruses, adenoviruses, coxsackie viruses, hepatitis A virus, and other agents that replicate in the human gastrointestinal tract. In addition, latex agglutination assays and nucleic acid hybridization techniques have been applied to the rapid detection of enteric viruses. It is likely that the application of a number of assay systems will promote accurate identification of a wide range of viral pathogens under different clinical, epidemiologic, and laboratory situations.


Asunto(s)
Antígenos Virales/análisis , Gastroenteritis/diagnóstico , Virosis/diagnóstico , Infecciones por Adenovirus Humanos/diagnóstico , Enterovirus/inmunología , Enterovirus Humano B/inmunología , Infecciones por Enterovirus/diagnóstico , Heces/microbiología , Femenino , Gastroenteritis/sangre , Gastroenteritis/líquido cefalorraquídeo , Gastroenteritis/inmunología , Gastroenteritis/orina , Humanos , Técnicas para Inmunoenzimas , Lactante , Recién Nacido , Masculino , Infecciones por Rotavirus/diagnóstico
8.
Clin Pediatr (Phila) ; 27(12): 609-12, 1988 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-3056651

RESUMEN

Mucormycosis is infrequently encountered in the pediatric population in any of its forms (nasopharyngeal, disseminated, pulmonary, or cutaneous) and generally is associated with the immunocompromised host. We present an adolescent with poorly controlled diabetes mellitus who developed a progressive skin lesion 3 weeks after a motor vehicle accident. Rhizopus species was isolated from the lesion, and the biopsy revealed a fungal vasculopathy. Control of her diabetes, aggressive surgical intervention and a 10-day course of antifungal therapy (amphotericin B) resulted in a favorable outcome. This article illustrates the importance of considering cutaneous fungal infections, especially those in the class zygomycetes, in the diabetic patient with unusual, severe or persistent skin lesions. Early recognition is essential in order to avoid morbidity and mortality from this unusual opportunistic infection.


Asunto(s)
Dermatomicosis/etiología , Diabetes Mellitus Tipo 1/complicaciones , Mucormicosis/etiología , Infección de Heridas/microbiología , Accidentes de Tránsito , Adolescente , Anfotericina B/uso terapéutico , Terapia Combinada , Dermatomicosis/tratamiento farmacológico , Dermatomicosis/cirugía , Femenino , Humanos , Mucormicosis/tratamiento farmacológico , Mucormicosis/cirugía , Rhizopus/aislamiento & purificación , Trasplante de Piel , Infección de Heridas/tratamiento farmacológico , Infección de Heridas/cirugía
11.
Pediatrics ; 70(3): 502, 1982 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-7110829
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA